Sugi Predict

Sugi Predict / Compounds / SCHEMBL61260

SCHEMBL61260

SCHEMBL61260

CN(C)CCCN(C1CCC(C(C)(C)C)CC1)S(=O)(=O)c1ccc2c(c1)C(=O)c1cc(S(=O)(=O)NC3CCC(C(C)(C)C)CC3)ccc1C2=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARG Q86W56 5/20 0.49
▸ ALDH1A1 P00352 5/20 0.39
▸ LMNA P02545 4/20 0.39
▸ NPSR1 Q6W5P4 3/20 0.39
▸ KMT2A Q03164 4/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ SLC6A3 Q01959 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ PIK3CG P48736 1/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL61324 0.91 SLC6A2 (0.40) PARGSMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL8768025 0.89 ALDH1A1 (0.40) PARGALDH1A1LMNANPSR1KMT2A
SCHEMBL90647 0.89 ALDH1A1 (0.40) PARGALDH1A1LMNANPSR1KMT2A
SCHEMBL29558779 0.89 ALDH1A1 (0.40) PARGALDH1A1LMNANPSR1KMT2A
SCHEMBL13366897 0.85 ALDH1A1 (0.36) PARGALDH1A1LMNANPSR1KMT2A
SCHEMBL60256 0.82 PARG (0.72) PARGALDH1A1LMNAKMT2AMEN1
SCHEMBL6113938 0.79 KDM4E (0.47) ALDH1A1LMNANPSR1KMT2AMEN1
SCHEMBL29558657 0.79 KDM4E (0.47) ALDH1A1LMNANPSR1KMT2AMEN1
SCHEMBL55488 0.68 TDP2 (0.40) PARGNPSR1KMT2AMEN1MAPT
SCHEMBL20302822 0.65 PARG (0.74) PARGALDH1A1LMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108314663-B Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof 多格伍德药品公司 2022-05-13 — — CN disclosed
US-9446021-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof DOGWOOD PHARMACEUTICALS, INC. (US) 2016-09-20 — — US disclosed
US-9446021-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof DOGWOOD PHARMACEUTICALS, INC. (US) 2016-09-20 — — US disclosed
US-20150313873-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof DOGWOOD PHARMACEUTICALS, INC. 2015-11-05 — — US disclosed
US-20150313873-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof DOGWOOD PHARMACEUTICALS, INC. 2015-11-05 — — US disclosed
US-9120754-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof DOGWOOD PHARMACEUTICALS, INC. (US) 2015-09-01 — — US disclosed
US-9120754-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof DOGWOOD PHARMACEUTICALS, INC. (US) 2015-09-01 — — US disclosed
US-20120129837-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof ALLERGAN SALES, LLC 2012-05-24 — — US disclosed
US-20120129837-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof ALLERGAN SALES, LLC 2012-05-24 — — US disclosed
US-8129519-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof ALLERGAN SALES, LLC 2012-03-06 — — US disclosed
US-8129519-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof ALLERGAN SALES, LLC 2012-03-06 — — US disclosed
WO-2010082912-A1 DERIVATIVES OF MULTI-RING AROMATIC COMPOUNDS AND USES AS ANTI-TUMOR AGENTS AVALON PHARMACEUTICALS (US) 2010-07-22 — — WO disclosed
US-20100137354-A1 DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF ALLERGAN SALES, LLC 2010-06-03 — — US disclosed
US-20100137354-A1 DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF ALLERGAN SALES, LLC 2010-06-03 — — US disclosed
WO-2010059142-A1 ANTHRAQUINONE DIOXIMES AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-05-27 — — WO disclosed
WO-2010059142-A1 ANTHRAQUINONE DIOXIMES AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129837-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof WNT1, CTNND1, CTNNB1 PARG 4086/4885ALDH1A1 1583/4885LMNA 1816/4885
US-20150313873-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof WNT1, CTNND1, CTNNB1 PARG 4086/4885ALDH1A1 1583/4885LMNA 1816/4885
US-20100137354-A1 DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF WNT1, CTNND1, CTNNB1 PARG 4086/4885ALDH1A1 1583/4885LMNA 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.